双参数MRI与多参数MRI引导经直肠超声靶向前列腺活检的阳性预测值比较
该回顾性横断面研究比较了双参数MRI与多参数MRI引导经直肠超声靶向前列腺活检的阳性预测值,共纳入1538例患者1860个病灶,校正病灶数量和PI-RADS评分后,两种方法对任何前列腺癌和临床显著前列腺癌的阳性预测值无差异(P=.61和.97),临床显著前列腺癌阳性预测值均为34%。
要点
- 双参数MRI与多参数MRI引导靶向活检对临床显著前列腺癌的阳性预测值无差异(34% vs 34%,P=.97)。
- 主动监测组任何前列腺癌阳性预测值双参数MRI较低(59% vs 73%,P=.04),但临床显著前列腺癌无差异。
- 校正病灶数量和PI-RADS评分后,两组任何前列腺癌阳性预测值无差异(55% vs 56%,P=.61)。
核心结论
- 校正病灶数量和PI-RADS评分后,双参数MRI与多参数MRI引导经直肠超声靶向前列腺活检对临床显著前列腺癌的阳性预测值无差异(34% vs 34%,P=.97)。
研究设计与样本
- 回顾性横断面研究,纳入2015年1月至2022年12月单中心接受双参数MRI或双参数MRI引导经直肠超声靶向前列腺活检的1538例患者(平均年龄67岁±8[SD])共1860个病灶,其中双参数MRI组849例(55%),多参数MRI组689例(45%),采用混合效应逻辑回归模型计算阳性预测值。
诊断标准与关键数值
- 临床显著前列腺癌定义为国际泌尿病理学会分级≥2;双参数MRI引导靶向活检任何前列腺癌阳性预测值55%(95%CI:51,59),临床显著前列腺癌34%(95%CI:30,38);多参数MRI引导靶向活检任何前列腺癌56%(95%CI:52,61),临床显著前列腺癌34%(95%CI:30,39);初诊活检男性双参数MRI任何前列腺癌64%(95%CI:59,69)、临床显著前列腺癌43%(95%CI:39,48),多参数MRI分别为67%(95%CI:59,75)和51%(95%CI:43,59),P=.65和.26;主动监测组双参数MRI任何前列腺癌59%(95%CI:49,69)、临床显著前列腺癌30%(95%CI:22,39),多参数MRI分别为73%(95%CI:65,89)和38%(95%CI:31,47),P=.04和.23。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Biparametric MRI (bpMRI) of the prostate is an alternative to multiparametric MRI (mpMRI), with lower cost and increased accessibility. Studies investigating the positive predictive value (PPV) of bpMRI-directed compared with mpMRI-directed targeted biopsy are lacking in the literature. Purpose To compare the PPVs of bpMRI-directed and mpMRI-directed targeted prostate biopsies. Materials and Methods This retrospective cross-sectional study evaluated men who underwent bpMRI-directed or mpMRI-directed transrectal US (TRUS)-guided targeted prostate biopsy at a single institution from January 2015 to December 2022. The PPVs for any prostate cancer (PCa) and clinically significant PCa (International Society of Urological Pathology grade ≥2) were calculated for bpMRI and mpMRI using mixed-effects logistic regression modeling. Results A total of 1538 patients (mean age, 67 years ± 8 [SD]) with 1860 lesions underwent bpMRI-directed (55%, 849 of 1538) or mpMRI-directed (45%, 689 of 1538) prostate biopsy. When adjusted for the number of lesions and Prostate Imaging Reporting and Data System (PI-RADS) score, there was no difference in PPVs for any PCa or clinically significant PCa (P = .61 and .97, respectively) with bpMRI-directed (55% [95% CI: 51, 59] and 34% [95% CI: 30, 38], respectively) or mpMRI-directed (56% [95% CI: 52, 61] and 34% [95% CI: 30, 39], respectively) TRUS-guided targeted biopsy. PPVs for any PCa and clinically significant PCa stratified according to clinical indication were as follows: biopsy-naive men, 64% (95% CI: 59, 69) and 43% (95% CI: 39, 48) for bpMRI, 67% (95% CI: 59, 75) and 51% (95% CI: 43, 59) for mpMRI (P = .65 and .26, respectively); and active surveillance, 59% (95% CI: 49, 69) and 30% (95% CI: 22, 39) for bpMRI, 73% (95% CI: 65, 89) and 38% (95% CI: 31, 47) for mpMRI (P = .04 and .23, respectively). Conclusion There was no evidence of a difference in PPV for clinically significant PCa between bpMRI- and mpMRI-directed TRUS-guided targeted biopsy. © RSNA, 2024 Supplemental material is available for this article.
引用
- Schieda N, Nisha Y, Hadziomerovic AR, et al. Comparison of Positive Predictive Values of Biparametric MRI and Multiparametric MRI-directed Transrectal US-guided Targeted Prostate Biopsy. Radiology. 2024. PMID: 38860899. doi:10.1148/radiol.231383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。